vs
渤健（BIIB）与Global Payments（GPN）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Global Payments的1.7倍（$2.3B vs $1.3B），Global Payments净利率更高（16.4% vs -2.1%，领先18.5%），渤健同比增速更快（-7.1% vs -47.1%），渤健自由现金流更多（$468.0M vs $347.0M），过去两年渤健的营收复合增速更高（-0.2% vs -25.9%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Global Payments Inc.是美国跨国金融科技企业，面向商户、发卡机构及消费者提供支付技术与相关服务，支持信用卡、借记卡、数字支付及非接触式支付的交易处理，2021年6月入选《财富》500强榜单。
BIIB vs GPN — 直观对比
营收规模更大
BIIB
是对方的1.7倍
$1.3B
营收增速更快
BIIB
高出40.0%
-47.1%
净利率更高
GPN
高出18.5%
-2.1%
自由现金流更多
BIIB
多$121.0M
$347.0M
两年增速更快
BIIB
近两年复合增速
-25.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.3B |
| 净利润 | $-48.9M | $217.5M |
| 毛利率 | 78.3% | 89.7% |
| 营业利润率 | -2.5% | 5.9% |
| 净利率 | -2.1% | 16.4% |
| 营收同比 | -7.1% | -47.1% |
| 净利润同比 | -118.3% | -61.6% |
| 每股收益（稀释后） | $-0.35 | $0.91 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBGPN
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $2.0B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.5B | $2.5B | ||
| Q3 24 | $2.5B | $2.6B | ||
| Q2 24 | $2.5B | $2.6B | ||
| Q1 24 | $2.3B | $2.4B |
净利润BIIBGPN
| Q4 25 | $-48.9M | $217.5M | ||
| Q3 25 | $466.5M | $635.2M | ||
| Q2 25 | $634.8M | $241.6M | ||
| Q1 25 | $240.5M | $305.7M | ||
| Q4 24 | $266.7M | $567.2M | ||
| Q3 24 | $388.5M | $315.1M | ||
| Q2 24 | $583.6M | $374.8M | ||
| Q1 24 | $393.4M | $313.3M |
毛利率BIIBGPN
| Q4 25 | 78.3% | 89.7% | ||
| Q3 25 | 73.4% | 72.3% | ||
| Q2 25 | 77.1% | 74.5% | ||
| Q1 25 | 74.1% | 61.8% | ||
| Q4 24 | 76.2% | 62.1% | ||
| Q3 24 | 74.1% | 63.6% | ||
| Q2 24 | 77.8% | 63.5% | ||
| Q1 24 | 76.3% | 61.9% |
营业利润率BIIBGPN
| Q4 25 | -2.5% | 5.9% | ||
| Q3 25 | 22.0% | 38.8% | ||
| Q2 25 | 28.1% | 21.8% | ||
| Q1 25 | 12.8% | 19.5% | ||
| Q4 24 | 11.9% | 33.1% | ||
| Q3 24 | 18.3% | 18.3% | ||
| Q2 24 | 28.3% | 22.3% | ||
| Q1 24 | 20.3% | 18.7% |
净利率BIIBGPN
| Q4 25 | -2.1% | 16.4% | ||
| Q3 25 | 18.4% | 31.6% | ||
| Q2 25 | 24.0% | 12.3% | ||
| Q1 25 | 9.9% | 12.7% | ||
| Q4 24 | 10.9% | 22.5% | ||
| Q3 24 | 15.8% | 12.1% | ||
| Q2 24 | 23.7% | 14.6% | ||
| Q1 24 | 17.2% | 12.9% |
每股收益（稀释后）BIIBGPN
| Q4 25 | $-0.35 | $0.91 | ||
| Q3 25 | $3.17 | $2.64 | ||
| Q2 25 | $4.33 | $0.99 | ||
| Q1 25 | $1.64 | $1.24 | ||
| Q4 24 | $1.82 | $2.23 | ||
| Q3 24 | $2.66 | $1.24 | ||
| Q2 24 | $4.00 | $1.47 | ||
| Q1 24 | $2.70 | $1.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $8.3B |
| 总债务越低越好 | $6.3B | $19.5B |
| 股东权益账面价值 | $18.3B | $22.9B |
| 总资产 | $29.4B | $53.3B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资BIIBGPN
| Q4 25 | — | $8.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.2B |
总债务BIIBGPN
| Q4 25 | $6.3B | $19.5B | ||
| Q3 25 | $6.3B | $13.3B | ||
| Q2 25 | $6.3B | $14.2B | ||
| Q1 25 | $4.5B | $15.0B | ||
| Q4 24 | $6.3B | $15.2B | ||
| Q3 24 | $4.5B | $15.2B | ||
| Q2 24 | $6.3B | $15.6B | ||
| Q1 24 | $6.3B | $15.6B |
股东权益BIIBGPN
| Q4 25 | $18.3B | $22.9B | ||
| Q3 25 | $18.2B | $22.7B | ||
| Q2 25 | $17.6B | $22.6B | ||
| Q1 25 | $17.0B | $22.2B | ||
| Q4 24 | $16.7B | $22.3B | ||
| Q3 24 | $16.4B | $22.8B | ||
| Q2 24 | $15.9B | $22.4B | ||
| Q1 24 | $15.2B | $22.2B |
总资产BIIBGPN
| Q4 25 | $29.4B | $53.3B | ||
| Q3 25 | $29.2B | $48.0B | ||
| Q2 25 | $28.3B | $48.5B | ||
| Q1 25 | $28.0B | $47.6B | ||
| Q4 24 | $28.0B | $46.9B | ||
| Q3 24 | $28.3B | $50.0B | ||
| Q2 24 | $26.8B | $50.8B | ||
| Q1 24 | $26.6B | $51.8B |
负债/权益比BIIBGPN
| Q4 25 | 0.34× | 0.85× | ||
| Q3 25 | 0.35× | 0.59× | ||
| Q2 25 | 0.36× | 0.63× | ||
| Q1 25 | 0.27× | 0.67× | ||
| Q4 24 | 0.38× | 0.68× | ||
| Q3 24 | 0.28× | 0.67× | ||
| Q2 24 | 0.40× | 0.70× | ||
| Q1 24 | 0.41× | 0.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $515.2M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $347.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 26.1% |
| 资本支出强度资本支出/营收 | 1.9% | 12.7% |
| 现金转化率经营现金流/净利润 | — | 2.37× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $2.0B |
8季度趋势，按日历期对齐
经营现金流BIIBGPN
| Q4 25 | $511.9M | $515.2M | ||
| Q3 25 | $1.3B | $768.7M | ||
| Q2 25 | $160.9M | $817.5M | ||
| Q1 25 | $259.3M | $555.1M | ||
| Q4 24 | $760.9M | $653.4M | ||
| Q3 24 | $935.6M | $1.7B | ||
| Q2 24 | $625.8M | $736.9M | ||
| Q1 24 | $553.2M | $416.3M |
自由现金流BIIBGPN
| Q4 25 | $468.0M | $347.0M | ||
| Q3 25 | $1.2B | $598.9M | ||
| Q2 25 | $134.3M | $665.4M | ||
| Q1 25 | $222.2M | $427.5M | ||
| Q4 24 | $721.6M | $469.4M | ||
| Q3 24 | $900.6M | $1.6B | ||
| Q2 24 | $592.3M | $557.7M | ||
| Q1 24 | $507.3M | $270.9M |
自由现金流率BIIBGPN
| Q4 25 | 20.5% | 26.1% | ||
| Q3 25 | 48.4% | 29.8% | ||
| Q2 25 | 5.1% | 34.0% | ||
| Q1 25 | 9.1% | 17.7% | ||
| Q4 24 | 29.4% | 18.7% | ||
| Q3 24 | 36.5% | 60.0% | ||
| Q2 24 | 24.0% | 21.7% | ||
| Q1 24 | 22.1% | 11.2% |
资本支出强度BIIBGPN
| Q4 25 | 1.9% | 12.7% | ||
| Q3 25 | 1.8% | 8.5% | ||
| Q2 25 | 1.0% | 7.8% | ||
| Q1 25 | 1.5% | 5.3% | ||
| Q4 24 | 1.6% | 7.3% | ||
| Q3 24 | 1.4% | 6.4% | ||
| Q2 24 | 1.4% | 7.0% | ||
| Q1 24 | 2.0% | 6.0% |
现金转化率BIIBGPN
| Q4 25 | — | 2.37× | ||
| Q3 25 | 2.73× | 1.21× | ||
| Q2 25 | 0.25× | 3.38× | ||
| Q1 25 | 1.08× | 1.82× | ||
| Q4 24 | 2.85× | 1.15× | ||
| Q3 24 | 2.41× | 5.48× | ||
| Q2 24 | 1.07× | 1.97× | ||
| Q1 24 | 1.41× | 1.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
GPN
| Integrated And Embedded Solutions | $869.3M | 65% |
| Point Of Sale And Software Solutions | $281.7M | 21% |
| Other | $178.4M | 13% |
